netFormulary NHS
North Central London
Joint Formulary
 Search
 Formulary Chapter 16: Amyloidosis - Full Chapter
16.01  Expand sub section  Other items
Anakinra
(Amyloidosis)
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • National Amyloidosis Clinic use only
    • Approval for
      • Chronic Granulomatous Disease (January 2013). Prior funding approval required
      • Familial Mediterranean Fever, Pericarditis and DIRA (RFL only; JFC May 2016). Prior funding approval required
      • Cryopyrin-Associated Periodic Syndrome (CAPS)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
   
Canakinumab
(Amyloidosis)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • National Amyloidosis Clinic use only
    • Approved for
      • Cryopyrin-Associated Periodic Syndrome (CAPS)
      • Periodic fever syndromes: TRAPS HIDS/MKD and FMF, in line with NHSE Commissioning Policy 200209P
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NHSE: Canakinumab for treating periodic fever syndromes: TRAPS, HIDS/MKD and FMF (ages 2 years and older)
   
Etanercept
(Amyloidosis)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

JFC approved Benepali as the brand of choice.

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • National Amyloidosis Clinic use only
    • Approved for:
      • TRAPS, HIDS
      • For use in other amyloidosis indications, contact pharmacy.  
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
 
   
Inotersen injection
(Amyloidosis)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
High Cost Medicine

See NICE HST for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • National Amyloidosis Clinic use only
    • Approved for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis, in line with NICE HST
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE HST9: Inotersen for treating hereditary transthyretin amyloidosis
   
Patisiran infusion
(Amyloidosis)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red

See NICE HST for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • National Amyloidosis Clinic use only
    • Approved for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy, in line with NICE HST
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE HST10: Patisiran for treating hereditary transthyretin amyloidosis
   
Tocilizumab
(Amyloidosis)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • National Amyloidosis Clinic use only
    • Approved for:
      • AA amyloidosis and/or recurrent fever syndrome in patients whose inflammatory activity has not responded to other agents. Subject to individual funding approval by NHS England (JFC July 2015)
      • Castleman's disease (JFC July 2015)
      • For use in other amyloidosis indications, contact pharmacy. 
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
   
Diflunisal
(Amyloidosis)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • National Amyloidosis Clinic use only
    • Approved for polyneuropathy progression in the hereditary ATTR subtype (ATTRm)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

GP - 1st

Medicines suitable for first-line use within primary care.

Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing. 

  

GP - 2nd

Medicines suitable for second-line use within primary care.

Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing. 

  

GP - Amber

Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised.  

Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC.

Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity.

  

GP - Red

Medicines which should normally be prescribed by specialists only (hospital only).

For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.

See link for the complete NCL Red List https://www.ncl-mon.nhs.uk/wp-content/uploads/2017/08/ncl_red_list.pdf

  

GP - Grey

Medicines on hospital formularies which have not been reviewed for suitability in primary care.  

Black

Medicines not recommended for routine use in primary or secondary care.

Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data.

  

netFormulary